Loading…

Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing

The 21kD GTPase Rac is an evolutionarily ancient regulator of cell shape and behavior. Rac2 is predominantly expressed in hematopoietic cells where it is essential for survival and motility. The hyperactivating mutation Rac2 also causes human immunodeficiency, although the mechanism remains unexplai...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2023-12, Vol.120 (52), p.e2310221120-e2310221120
Main Authors: Mishra, Abhinava K, Rodriguez, Melanie, Torres, Alba Yurani, Smith, Morgan, Rodriguez, Anthony, Bond, Annalise, Morrissey, Meghan A, Montell, Denise J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 21kD GTPase Rac is an evolutionarily ancient regulator of cell shape and behavior. Rac2 is predominantly expressed in hematopoietic cells where it is essential for survival and motility. The hyperactivating mutation Rac2 also causes human immunodeficiency, although the mechanism remains unexplained. Here, we report that in Drosophila, hyperactivating Rac stimulates ovarian cells to cannibalize neighboring cells, destroying the tissue. We then show that hyperactive Rac2 stimulates human HL60-derived macrophage-like cells to engulf and kill living T cell leukemia cells. Primary mouse Rac2 bone-marrow-derived macrophages also cannibalize primary Rac2 T cells due to a combination of macrophage hyperactivity and T cell hypersensitivity to engulfment. Additionally, Rac2 macrophages non-autonomously stimulate wild-type macrophages to engulf T cells. Rac2 also enhances engulfment of target cancer cells by chimeric antigen receptor-expressing macrophages (CAR-M) in a CAR-dependent manner. We propose that Rac-mediated cell cannibalism may contribute to Rac2 human immunodeficiency and enhance CAR-M cancer immunotherapy.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.2310221120